dc.contributor.author
Seiffert, Nicolai
dc.contributor.author
Tang, Peter
dc.contributor.author
Keshi, Eriselda
dc.contributor.author
Reutzel-Selke, Anja
dc.contributor.author
Moosburner, Simon
dc.contributor.author
Everwien, Hannah
dc.contributor.author
Wulsten, Dag
dc.contributor.author
Napierala, Hendrik
dc.contributor.author
Pratschke, Johann
dc.contributor.author
Sauer, Igor M.
dc.contributor.author
Hillebrandt, Karl H.
dc.contributor.author
Struecker, Benjamin
dc.date.accessioned
2023-03-13T13:35:59Z
dc.date.available
2023-03-13T13:35:59Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/38343
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-38062
dc.description.abstract
Background: Many patients suffering from peripheral arterial disease (PAD) are dependent on bypass surgery. However, in some patients no suitable replacements (i.e. autologous or prosthetic bypass grafts) are available. Advances have been made to develop autologous tissue engineered vascular grafts (TEVG) using endothelial colony forming cells (ECFC) obtained by peripheral blood draw in large animal trials. Clinical translation of this technique, however, still requires additional data for usability of isolated ECFC from high cardiovascular risk patients. Bovine carotid arteries (BCA) were decellularized using a combined SDS (sodium dodecyl sulfate) -free mechanical-osmotic-enzymatic-detergent approach to show the feasibility of xenogenous vessel decellularization. Decellularized BCA chips were seeded with human ECFC, isolated from a high cardiovascular risk patient group, suffering from diabetes, hypertension and/or chronic renal failure. ECFC were cultured alone or in coculture with rat or human mesenchymal stromal cells (rMSC/hMSC). Decellularized BCA chips were evaluated for biochemical, histological and mechanical properties. Successful isolation of ECFC and recellularization capabilities were analyzed by histology.
Results: Decellularized BCA showed retained extracellular matrix (ECM) composition and mechanical properties upon cell removal. Isolation of ECFC from the intended target group was successfully performed (80% isolation efficiency). Isolated cells showed a typical ECFC-phenotype. Upon recellularization, co-seeding of patient-isolated ECFC with rMSC/hMSC and further incubation was successful for 14 (n = 9) and 23 (n = 5) days. Reendothelialization (rMSC) and partial reendothelialization (hMSC) was achieved. Seeded cells were CD31 and vWF positive, however, human cells were detectable for up to 14 days in xenogenic cell-culture only. Seeding of ECFC without rMSC was not successful.
Conclusion: Using our refined decellularization process we generated easily obtainable TEVG with retained ECM- and mechanical quality, serving as a platform to develop small-diameter (< 6 mm) TEVG. ECFC isolation from the cardiovascular risk target group is possible and sufficient. Survival of diabetic ECFC appears to be highly dependent on perivascular support by rMSC/hMSC under static conditions. ECFC survival was limited to 14 days post seeding.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Endothelial Colony forming cells (ECFC)
en
dc.subject
Mesenchymal stromal cells (MSC)
en
dc.subject
Tissue engineering
en
dc.subject
Bovine carotid artery
en
dc.subject
Decellularization
en
dc.subject
Recellularization
en
dc.subject
Target group specific cells
en
dc.subject
Impaired cell function
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
In vitro recellularization of decellularized bovine carotid arteries using human endothelial colony forming cells
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
15
dcterms.bibliographicCitation.doi
10.1186/s13036-021-00266-5
dcterms.bibliographicCitation.journaltitle
Journal of Biological Engineering
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.volume
15
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
Springer Nature DEAL
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
33882982
dcterms.isPartOf.eissn
1754-1611